Analyzing immune responses to different COVID-19 vaccines using advanced techniques
Comparative Genetic and Immune Response Analysis of Different COVID-19 Vaccine Candidates Using Multi-OMICS Approach
NA · University Hospital Tuebingen · NCT04873128
This study is testing how different COVID-19 vaccines affect people's immune responses and side effects to help improve future vaccines.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 110 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital Tuebingen (other) |
| Locations | 1 site (Tübingen) |
| Trial ID | NCT04873128 on ClinicalTrials.gov |
What this trial studies
This study investigates the varying immune responses and side effects experienced by individuals receiving different COVID-19 vaccines. By employing a Multi-OMICS approach, researchers will analyze blood samples to gather data from multiple biological levels, aiming to understand the genetic factors influencing these responses. The study seeks to clarify the unpredictable nature of vaccine reactions and explore long-term protection against SARS-CoV-2. Ultimately, the findings could inform the development of better vaccines and therapeutic strategies.
Who should consider this trial
Good fit: Ideal candidates include healthy individuals over 18 who have either recovered from COVID-19 or have not been infected, as well as vaccinated individuals experiencing complications post-vaccination.
Not a fit: Patients who are under 18 or those who cannot provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved COVID-19 vaccines and personalized vaccination strategies based on genetic predispositions.
How similar studies have performed: Other studies utilizing Multi-OMICS approaches have shown promise in understanding immune responses, suggesting potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Group 1 * Healthy donors (HD) who had recovered from COVID-19 disease and/or HD who did not have COVID-19 disease in the past * and who will receive the COVID-19 vaccine or a COVID19 vaccine candidate or other protective vaccines * HD who did receive one dose of a specific COVID19 vaccine but who will receive a different vac-cine for her/his second vaccination for completion of the immunization * Age \> 18 years Group 2 * Vaccinated subjects who are diagnosed with central thrombosis, anaphylactic shock or other major or minor complications such as atopic dermatitis (for example) after vaccination. * Age \> 18 years Exclusion Criteria: Group 1 and 2 - Missing informed consent of the subject
Where this trial is running
Tübingen
- University Hospital Tübingen — Tübingen, Germany (RECRUITING)
Study contacts
- Study coordinator: Olaf Rieß, Prof. Dr.
- Email: olaf.riess@med.uni-tuebingen.de
- Phone: +49 7071 29
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Genetic Predisposition, Multi-OMICS, COVID-19, Side effect, Immun response, Vaccination, Memory response